



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/866,279	05/30/1997	SUSAN M. DYMECKI	234805	9567

7590 02/25/2003

CUSHMAN DARBY & CUSHMAN  
INTELLECTUAL PROPERTY GROUP OF  
PILLSBURY MADISON & SUTRO LLP EAST TOW  
1100 NEW YORK AVE N W NINTH FLOOR  
WASHINGTON, DC 200053918

EXAMINER

FALK, ANNE MARIE

ART UNIT PAPER NUMBER

1632

DATE MAILED: 02/25/2003

36

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

08/866,279

Applicant(s)

DYMECKI, SUSAN M.

Examiner

Anne-Marie Falk, Ph.D.

Art Unit

1632

-- Th MAILING DATE of this communication appears on th cover sheet with th correspondenc address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 04 December 2002.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-21, 50-52, 55-59 and 62-65 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 2-21, 50-52, 55-59, and 62-65 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

### DETAILED ACTION

The response filed December 4, 2002 (Paper No. 35) has been entered. Claims 1, 20, 51, 52, 55-57, 59, and 62-64 have been amended. Claims 22-49, 53, 54, 60, and 61 have been cancelled.

Accordingly, Claims 1-21, 50-52, 55-59, and 62-65 remain pending in the instant application.

The following rejections are reiterated or newly applied and constitute the complete set of rejections being applied to the instant application. Rejections and objections not reiterated from the previous office action are hereby withdrawn.

#### *Claim Rejections - 35 USC § 112*

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

#### *Enablement*

Claims 2-51, 55-58, and 62-65 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a transgenic mouse comprising an FLP recombinase transgene under the control of a tissue-specific promoter and a reporter gene under the control of a non-tissue-specific (ubiquitous) promoter, wherein the reporter gene comprises a disruption comprising two Flp-recognition sequences in direct repeat orientation, such that the reporter gene produces active product only when in the recombined form, does not reasonably provide enablement for transgenic mice having the wide variety of different combinations of Flp-recognition sequences and transgenes, as broadly claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Art Unit: 1632

The specification fails to provide an enabling disclosure for the full scope of the claims because the phenotype of a transgenic mouse is unpredictable for reasons of record advanced on pages 2-6 of the Office Action of Paper No. 22 (mailed 10/25/00), on pages 2-8 of Paper No. 26 (mailed 7/18/01), and on pages 2-3 of the Office Action of Paper No. 33 (mailed 6/5/02). Thus, the specification fails to teach how to use the full scope of the claimed transgenic mice. In the absence of disclosure of a transgene-dependent phenotypic alteration, one skilled in the art would not know how to use the claimed transgenic mice over the full scope. Thus, one skilled in the art would have been required to engage in undue experimentation in order to make and use the claimed transgenic mice over the full scope.

The claims must be congruent with the asserted utility of the invention, which in the instant case is cell fate mapping. The instant claims are not congruent with the asserted utility of cell fate mapping. In the interview of March 29, 2001, the inventor provided convincing arguments for the utility of cell fate mapping. The Examiner evaluated enablement for this utility with respect to the application as-filed and identified a scope of enablement consistent with this utility, the only asserted utility for which a scope of enablement exists. However, the claims remain broader than the scope of enablement.

At page 7, paragraph 3 of the response, Applicants question the reasoning behind the separate rejection of Claim 2-60 and 62-65 and Claim 1. Applicants should note that the scope of enablement for Claim 1 is different from the scope of enablement for Claims 2-60 and 62-65.

At page 7, paragraph 3 of the response, Applicants assert that the amendment to Claim 1 should resolve the rejection as it pertains to Claims 2-21 and 50-51 since these claims depend from Claim 1 and are more narrow in scope than Claim 1. However, as clearly indicated in the rejection, the scope of enablement for Claims 2-21 and 50-51 is different from the scope of enablement for Claim 1. Furthermore, the suggestion that claims that are more narrow than an enabled claim automatically makes them enabled is incorrect, as a broad claim is permitted to cover a vast number of inoperative embodiments. ~

Art Unit: 1632

At page 7, paragraph 3 of the response, Applicants assert that the specification is not limited to the utility of cell fate mapping, as it also discusses making mutations in specific cells and site specific integration of transgenes. Applicants offer no further arguments with regard to **enablement** for these utilities. Further, it is noted that enablement for these utilities has been fully evaluated in great detail in the Office Actions of Paper Nos. 22 (mailed 10/25/00), 26 (mailed 7/18/01), 30 (mailed 2/11/02), and 33 (mailed 6/5/02).

*New Matter*

With regard to the new matter rejection regarding the term “ubiquitous promoter” (applied to Claims 54 and 61, now cancelled), the Examiner accepts the passage on pages 16-17 of the specification to which Applicants refer as implicit support for the term “ubiquitous promoter.” Although the passage does not provide literal support for the term, the passage refers to “regulatory regions for ubiquitous expression.” At page 16, paragraph 2, the passage refers to a number of “regulatory regions” including promoters. Amended Claims 52 and 59 and the claims which depend from them, now recite a “ubiquitous promoter.”

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 51 stands and Claims 52, 55-57, 59, and 62-65 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 51 remains indefinite in its recitation of “growth/differentiation factors and their receptors” because the metes and bounds are not clearly set forth. The specification does not offer a definition of this term that would serve to define the metes and bounds.

Art Unit: 1632

At page 10, paragraphs 1 and 3 of the response, Applicants argue that gene products constituting growth or differentiation factors and their receptors were well known at the time the application was filed and would be immediately recognized by a person of skill in the art. At paragraph 3, Applicants refer to a variety of "growth factors." At page 11, paragraph 2 of the response, Applicants refer to a variety of "differentiation factors." However, the claim language does not recite "growth factors" or "differentiation factors" but rather recites "growth/differentiation factors." The metes and bounds of this term are not clearly set forth and the specification does not offer a definition of this term. Providing a definition for the term "differentiation" does not serve to elucidate the definition of the term "growth/differentiation factors."

Claim 52 and 55-57 are indefinite in their use of the term "intergrated" because this appears to be a typographical error. Claim 52 as pending prior to this amendment used the correct spelling "integrated." See the amendment of Paper No. 32, submitted March 18, 2002. This rejection is necessitated by Applicants amendment.

Claims 59 and 62-65 are indefinite in their recitation of "said Flp transgene" in step (c) because the term lacks antecedent basis. The claim has been amended in steps (a) and (b) to recite an "Flp recombinase transgene." This rejection is necessitated by Applicants amendment.

### *Conclusion*

Claim 1 is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing

Art Unit: 1632

date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne-Marie Falk whose telephone number is (703) 306-9155. The examiner can normally be reached Monday through Thursday and alternate Fridays from 10:00 AM to 7:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst, William Phillips, whose telephone number is (703) 305-3482.

Anne-Marie Falk, Ph.D.

*Anne-Marie Falk*  
ANNE-MARIE FALK, PH.D.  
PRIMARY EXAMINER